Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 15, 2022 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,022 | -- | -- | |
| Jul 15, 2022 | EVP and CFO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,758 | -- | -- | |
| Jul 12, 2022 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,022 | -- | -- | |
| Jul 07, 2022 | SVP/GM, Vascular Access | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,195 | -- | -- | |
| Jul 07, 2022 | Director, President and CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 50,139 | -- | -- | |
| Jul 07, 2022 | SVP Global Operations and R&D | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,945 | -- | -- | |
| Jul 07, 2022 | SVP Quality and Regulatory | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,452 | -- | -- | |
| Jul 07, 2022 | EVP and CFO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,357 | -- | -- | |
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 7,079 | -- | -- | |
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,195 | -- | -- |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.